Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
Location status: Recruiting
NCT Number: NCT07636525
The main reason for this research study is to understand whether the sleep habits of 11-12 years-olds impact their response to a vaccine. The vaccine is called MCV4. It protects against meningococcal illness, which is rare but can be severe. The American Academy of Pediatrics recommends that the vaccine be given at age 11 or 12. The vaccine has been approved for youth in this age range for over 20 years and is one of the vaccines that primary care doctors typically give around this age. However, nobody has studied how sleep affects children's response to it. This could be important because research on adults suggests that sleep affects the immune system. We want to look at that issue in a younger age range.
Participating families will be asked to have their child keep their regular sleep schedule during the 5-week study, without much variation. During that time, they will wear a special wristwatch at night to track their sleep. Each day they will fill out a short online form. They and a parent/guardian will come to Cincinnati Children's twice. Each visit will last 1 - 1 ½ hours. The first visit will happen at the end of the 1st week. The second is at the end of the 5th week. During visits, they will fill out forms and we will get data from the wristwatch. During the first visit, the participating child would get the vaccine. During the second, they will have a blood test.
Interested in participating?
Request Info11 year–12 year
All sexes
Observational
Cincinnati, Ohio, 45229, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 month post-vaccination
Measured via serum bactericidal assay (SBA), which measures the ability of serum antibodies to kill the meningococcus bacteria in the presence of complement protein. The primary outcome will be the proportion of individuals in each group with a titer greater than or equal to 1:8 for each MCV4 serotype (A, C, W, Y), which is a strong correlate of protection.
Time frame: Each of the 3 days immediately following vaccination.
Each morning, secure online survey links will be sent via text message or email to the youth, parent or both. Youth will be asked to rate online the 8 most common side effects of meningococcal vaccination (e.g., injection site pain, headache) on a 5-point scale from not present to severe. A printed survey and phone number will be provided for call-in ratings if online entry fails.
Time frame: Daily for weeks 1 and 2, then again for week 4 (immediately before the final visit).
Sleep (adherence) will be objectively measured during remote monitoring via wristwatch-like devices, checked for artifacts against self-reported sleep on a daily diary. The primary adherence measure will be sleep duration (onset to offset). Secondarily, sleep quality will be defined as the percent of time from onset to offset spent asleep.
Contact information is provided by the study sponsor or research team.
Children's Hospital Medical Center, Cincinnati
Other
Sleep and Adolescent Vaccine Immunogenicity (SAVI) Pilot Study
Acronym: SAVI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07236034
Vaccination, Vaccination Promotion
Worcester, Massachusetts, United States
View Trial DetailsNCT07592260
Malnutrition Severe, Vaccination
Ngouri, Lac Region, Chad
View Trial DetailsNCT06890403
Behavior, Communication
New York, United States
View Trial DetailsNCT06587243
Behavior, Communication
New York, United States
View Trial Details